Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts (EVAsION)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03977753 |
|
Recruitment Status :
Recruiting
First Posted : June 6, 2019
Last Update Posted : November 30, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Human papillomavirus (HPV) infection is very common, as most people will experience infection during their lifetime. The most common manifestation of HPV infection is common warts. Common warts may appear at any age.
Conventional treatments can be used to treat warts and they are based on two mechanisms: stimulation of cellular immunity against HPVs or destruction of the lesion. These treatments are based on the location of the wart and the degree of the symptoms.
No specific antiviral therapy is available to cure warts and today, there is no treatment that allows the definitive eradication of the virus.
The 2LVERU® has been available for more than 20 years, and has received a marketing authorization in Belgium by the Federal Agency for Medicines and Health Products (FAMHP). It is used as an immune regulator in the treatment of common warts (verruca vulgaris), flat warts (verruca plana) or plantar warts (verruca plantaris) caused by Human Papillomavirus. Since 2LVERU® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the disappearance of warts.
The purpose of this placebo-controlled, randomized, double-blind trial is the comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Common Wart Flat Wart Plantar Wart | Drug: 2LVERU® or 2LVERU® JUNIOR Drug: Placebo | Phase 4 |
The study duration will be maximum 45 months with 36 months of inclusion and 9 months of follow-up.
Patients aged 3 years and older who present common warts (Verruca vulgaris), and/or plantar warts (Verruca plantaris), and/or flat warts (Verruca plana) during a visit with their dermatologist/general practitioner.
The total number of patients to include will be 162.
Primary objective:
Comparison of the efficacy of the treatment on the disappearance of warts at the end of treatment (6-month visit) between the 2LVERU® JUNIOR and 2LVERU® versus the placebo group.
Secondary objectives
- Comparison of the efficacy of the treatment on the disappearance of warts at 4 months between groups.
- Comparison of the efficacy of the treatment on the level of disappearance (4 levels) of warts at 4 months and 6 months (end of the treatment) between groups
- Comparison of the efficacy of the treatment on the recurrence of warts 3 months after the end of treatment between groups
- Compare the pain related to warts during the study between groups
- Safety issues.
Treatment phase:
- Group n°1 = 2LVERU® JUNIOR / 2LVERU® (6 months of treatment)
- Group n°2 = Placebo (6 months of treatment)
Post-treatment Follow-up phase: 3 months
Treatment will be considered successful if the following three criteria are met for all treated warts as described at the baseline visit:
- Normal skin colour at the wart site
- Normal skin texture at the wart site
- Normal touch at the wart site Treatment will be considered a failure, at the end of the treatment, if at least one of the above three criteria is not met for all treated warts as described at the baseline visit.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 162 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Triple (Participant, Investigator, Outcomes Assessor) |
| Masking Description: | Double-blind study |
| Primary Purpose: | Treatment |
| Official Title: | Study to Evaluate the Efficacy of 2LVERU® JUNIOR and 2LVERU® on the Treatment of Warts. |
| Actual Study Start Date : | February 17, 2020 |
| Estimated Primary Completion Date : | December 16, 2023 |
| Estimated Study Completion Date : | March 16, 2024 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 2LVERU®/2LVERU® JUNIOR
Group N°1: 2LVERU® or 2LVERU® JUNIOR treatment (6 months of treatment)
|
Drug: 2LVERU® or 2LVERU® JUNIOR
The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day. |
|
Placebo Comparator: Placebo
Group N°2: Placebo treatment (6 months of treatment)
|
Drug: Placebo
The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule/day. |
- Disappearance of warts at the end of treatment (6-month visit) [ Time Frame: 6 months ]A wart will be considered as disappeared if the colour and texture of the skin has returned to normal and can no longer be felt to the touch.
- Disappearance of warts at 4 months. [ Time Frame: 4 months ]
- Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 4 months [ Time Frame: 4 months ]
- Warts recurrence at 9 months [ Time Frame: 9 months ]
- Pain evaluation during the study by visual analogic scale and consumption of antalgic medication. [ Time Frame: 6 months ]Minimum value: 0 (better outcome) Maximum Value: 10 (worse outcome)
- Safety: occurence of adverse events (AEs) and severe adverse events (SAEs), considered as related or not to the study drug. [ Time Frame: 6 months ]
- Disappearance level (total disappearance, partial disappearance (50%), no modification, increase of number of warts) at 6 months [ Time Frame: 6 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 3 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients, male or female, aged 3 years and older,
- Patients with common warts (Verruca vulgaris), and/or plantar warts (Verruca plantaris), and/or flat warts (Verruca plana),
- Patients (and/or parents if necessary) having the faculties to understand and respect the constraints of the study,
- Signature of the Informed Consent Form by the patient (and/or parents if necessary).
Exclusion Criteria:
- Patients who have received any curative warts treatment in the previous 2 months prior to the study,
- Patients who have received any homeopathic treatment in the previous 2 months prior to the study,
- Patients under immunosuppressive treatment,
- Patients having received immunotherapy or micro-immunotherapy during the last 6 months,
- Patients with known lactose intolerance,
- Pregnant or breastfeeding women,
- Patients who participated in a clinical study in the previous 2-months period,
- Patients (and/or parents of patients if necessary) who are not sufficiently motivated to engage on the total study follow-up period, or likely to travel or to move before the end of the study,
- Patients with severe immunodeficiency disease requiring long term treatment (*) or patients under chemotherapy or radiotherapy,
- Patients under listed homeopathic or phytotherapy treatment (see protocol),
- Patients addicted to or using recreational drugs,
- Patient under guardianship and/or curators, (*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03977753
| Contact: Charlotte Bolle | (0)497 49 13 74 ext +32 | charlotte.bolle@labolife.com |
| Belgium | |
| Private Practice | Withdrawn |
| Arlon, Belgium, 6700 | |
| Clinique Saint-Luc (Bouge) | Recruiting |
| Bouge, Belgium, 5004 | |
| Contact: Audrey SCHILS, Dr | |
| Principal Investigator: Audrey SCHILS, Dr | |
| Private Practice | Terminated |
| Brussel, Belgium, 1020 | |
| Private Practice | Terminated |
| Ecaussinnes-d'enghien, Belgium, 7190 | |
| Private Practice | Suspended |
| Fontaine l'Êveque, Belgium, 6140 | |
| Private Practice | Recruiting |
| Gent, Belgium, 9942 | |
| Contact: Filip Dr Verrue | |
| Principal Investigator: Filip Dr Verrue | |
| Private Practice | Recruiting |
| Gozée, Belgium, 6534 | |
| Contact: Françoise WALRAVENS, Dr | |
| Principal Investigator: Françoise WALRAVENS, Dr | |
| Private Practice | Recruiting |
| Hamme-Mille, Belgium, 1320 | |
| Contact: Susanne Dr Hausdorfer | |
| Principal Investigator: Susanne Dr Hausdorfer | |
| Private Practice | Withdrawn |
| Juprelle, Belgium, 4450 | |
| Private Practice | Withdrawn |
| Mons, Belgium, 7000 | |
| Private Practice | Recruiting |
| Namur, Belgium, 5000 | |
| Contact: Bernadette BLOUARD, Dr | |
| Principal Investigator: Bernadette BLOUARD, Dr | |
| Private Practice | Withdrawn |
| Namur, Belgium, 5000 | |
| Private Practice | Recruiting |
| Oisquercq, Belgium, 1480 | |
| Contact: Laurence TOURNE, Dr | |
| Principal Investigator: Laurence TOURNE, Dr | |
| Private Practice | Withdrawn |
| Plancenoit, Belgium, 1380 | |
| Private Practice | Withdrawn |
| Quiévrain, Belgium, 7380 | |
| Private Practice | Recruiting |
| Saint-Symphorien, Belgium, 7030 | |
| Contact: Nathalie BEAUCHOT, Dr | |
| Principal Investigator: Nathalie BEAUCHOT, Dr | |
| Private Practice | Recruiting |
| Seneffe, Belgium, 7180 | |
| Contact: Kristel MESTDAGH, Dr | |
| Principal Investigator: Kristel MESTDAGH, Dr | |
| Private Practice | Recruiting |
| Wavre, Belgium, 1300 | |
| Contact: Wolfram FINK, Dr | |
| Principal Investigator: Wolfram Fink, Dr | |
| Responsible Party: | Labo'Life |
| ClinicalTrials.gov Identifier: | NCT03977753 |
| Other Study ID Numbers: |
LLB-2019-02 |
| First Posted: | June 6, 2019 Key Record Dates |
| Last Update Posted: | November 30, 2022 |
| Last Verified: | November 2022 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
|
Warts Papillomavirus Infections DNA Virus Infections Virus Diseases Infections |
Skin Diseases, Viral Tumor Virus Infections Skin Diseases, Infectious Skin Diseases |